| ID | 1034 |
| Name of the vaccine | Tripedia |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Toxoid |
| Nucleic acid content | DNA |
| Age | 6 weeks to 7 years |
| Description of the vaccine | Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed. |
| Name of the manufacturer | Sanofi Pasteur, Inc. |
| Name of the manufacturing country | NA |
| Year of manufacture | 1996 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | Reduces the risk of developing diphtheria and protection lasts around 10 years. |
| Vaccine formulation | Suspension for injection |
| Dosage | Three doses, gap of 4-8 weeks. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Immunization against diphtheria, tetanus and pertussis simultaneously. |
| Export | Distributed by Aventis Pasteur Inc. (AvP) |
| Approval | US FDA |
| Adjuvant | Aluminium potassium sulphate |
| Repurposing | For tetanus and acellular pertussis. |
| Side effects of vaccine | Injection site reactions, fever, irritability, drowsiness and vomiting. |
| Post vaccination | NA |
| Dose type | Combination (3 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=354&keywords= |
| Other name | NA |
| Additional Links | NA
|